SCTX NASDAQ
Scribe Therapeutics Inc.
1W: -21.1%
1M: -45.7%
YTD: +11.9%
$16.79
-0.39 (-2.24%)
Weekly Expected Move ±19.0%
$10
$14
$17
$20
$23
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$271.7M
52W Range15-39.6
Volume473,876
Avg Volume342,596
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOBenjamin L. Oakes
Employees89
SectorHealthcare
IndustryBiotechnology
IPO Date2026-07-24
Websitescribetx.com
1150 MARINA VILLAGE PARKWAY
Alameda, CA 94501
US
Alameda, CA 94501
US
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Latest News
Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts
Cathie Wood's weekly recap: buys $25M of CoreWeave, trims $40M in Bitcoin ETF
Cathie Wood's Ark weekly recap: buys Meta, gene-editing stocks while cutting Alphabet
Cathie Wood's weekly recap: loads Rocket Lab, Block; cuts Palantir, Tempus AI
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ELI LILLY & Co | 0 | — | 2026-07-23 |